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Abstract 
Pattern hair loss is the most common form of hair loss in both women and men. Male pattern hair loss, 
also termed male androgenetic alopecia (M-AGA), is an androgen-dependent trait that is 
predominantly genetically determined. Androgen-mediated mechanisms are probably involved in 
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FPHL in some women but the evidence is less strong than in M-AGA; and other non-androgenic 
pathways, including environmental influences, may contribute to the aetiology. Genome-wide 
association studies (GWASs) have identified several genetic loci for M-AGA and have provided better 
insight into the underlying biology. However, the role of heritable factors in female pattern hair loss 
(FPHL) is largely unknown. Recently published studies have been restricted to candidate gene 
approaches and could not clearly identify any susceptibility locus/gene for FPHL but suggest the 
aetiology differs substantially from that of M-AGA. Hypotheses about possible pathomechanisms of 
FPHL as well as the results of the genetic studies performed to date are summarized.  
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Introduction 
Female pattern hair loss (FPHL) is the most common hair loss disorder in women. Currently available 
therapies for FPHL are unsatisfactory, and there is a demand for new treatment strategies. FPHL 
typically presents as a diffuse reduction in hair density that mainly affects the mid and frontal regions 
of the scalp with preservation of the frontal hairline (Fig 1). Some women show a more pronounced 
frontal accentuation (the Christmas tree pattern) (1) and some have a more global reduction in hair 
density involving the sides and back of the scalp. Deep recession of the fronto-temporal hairline and 
true vertex balding, as seen in men, occasionally occur in women but are uncommon. Nevertheless, 
the regressive changes that occur in hair follicles in FPHL are similar if not identical to those that occur 
in male balding. It is well-established that male balding is a genetically determined androgen-
dependent trait (male androgenetic alopecia, M-AGA) and it has long been assumed that FPHL shares 
the same aetiology, hence the term female androgenetic alopecia is often applied to this condition. 
However, the role of androgens in causing FPHL is less clear than in men. The genetic studies 
performed so far have not led to any firm conclusions but rather suggest different pathways for M-AGA 
and FPHL. 
In this review, we summarize what is known about the aetiology of FPHL and its relationship to M-
AGA. Our main focus is on the results of genetic studies performed within the last decade. We also 
discuss the role of endocrine and other factors in the pathogenesis.  
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Prevalence 
Published data on the prevalence of FPHL show some variation between studies, perhaps reflecting 
the difficulty in classifying mild forms of the condition. However, all show an increasing prevalence with 
age. Studies in women of white European ethnicity in the USA,(2) UK(3) and Australia(4) record a 
prevalence of 3-12% in the third decade, rising to 14-28% in the sixth decade and 29-56% in women 
aged 70 and over. Reported prevalence rates in East Asian women are lower, reaching 12-25% in 
over 70 group.(5-7)  Although the onset is after puberty in the great majority of cases pattern hair loss 
has been reported in children as young as 6 years of age.(8)  
 
Pathophysiology 
Pathology 
The pathologic changes in pattern hair loss appear identical in men and women. There is a reduction 
in the duration of anagen and prolongation of telogen.(9) The time to exogen is unchanged but there is 
an increasing delay in the onset of the next anagen phase leading to prolongation of the latent phase 
(kenogen) where the follicle is not producing a hair and is ‘empty’.(10) Follicles then undergo a 
process of miniaturisation, possibly ending in follicular deletion.(11) The precise cause for this process 
of follicular regression is unclear.  
Arrector pili muscle degeneration 
In a recent study of eight scalp biopsies from patients with AGA degeneration of the arrector pili 
muscle (APM) and replacement by fat tissue was observed.(12) The precise mechanism remains 
unclear but the authors speculated that degeneration of APM might be related to depletion of follicular 
stem or progenitor cells. The authors did not state whether samples were from men or women. 
Inflammation/immunity/apoptosis of hair follicle 
A role for inflammation in the pathogenesis of androgenetic alopecia was proposed by Jaworsky et 
al.(13)  Later, Whiting reported the presence of inflammation in 37% of biopsy samples from patients 
with FPHL compared with 12% of control subjects.(14) Scalp biopsies from 17 women with FPHL and 
five healthy females were included in the study of Ramos et al.(15) They observed a higher apoptosis 
index and prominent mononuclear microinflammation among the miniaturized follicles. Furthermore, 
they reported a positive correlation between apoptosis and perifollicular inflammation. Kolivras et al. 
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reported presence of T-cells in tissue samples of a total of 28 patients with AA but not in the tissue 
samples of 31 cases with “pattern hair loss”.(16) Mahé et al. studied the level of interleukin (IL)-1 alpha 
production in plucked human anagen hair and suggested that IL-1 has a negative effect on hair growth 
in patients with AGA.(17)  
Whether inflammation plays a causative role in pattern hair loss is unclear although treatment with 
anti-inflammatory agents or immunosuppressive drugs is not conspicuously associated with its 
reversal.  
 
Aetiology 
Sex steroid hormones 
The term “female androgenetic alopecia“ was introduced in 1977 by the dermatologist Ludwig,(18) 
implying an androgen-dependent mechanism underlying FPHL. There is little doubt that severe 
hyperandrogenism, such as occurs due to androgen-secreting adrenal or ovarian tumours, does cause 
scalp hair loss in women, and was recognised prior to Hamilton’s seminal publication on the causative 
role of testosterone in M-AGA.(19) Some studies have found elevated androgen levels or an elevated 
androgen/oestrogen ratio in women with FPHL,(20, 21) though generally of minor degree, and one 
ultrasound study has reported an increased frequency of polycystic ovaries.(22) Alopecia is frequently 
mentioned as a feature of polycystic ovary syndrome (PCOS) though it is less common than hirsutism. 
Two studies from Turkey and the USA reported the prevalence of FPHL in women diagnosed with 
PCOS as 34.8% and 22% respectively.(23, 24) However, not all studies have found evidence of 
hyperandrogenism in FPHL(25) and in all studies there is a variable proportion of subjects without 
clinical or biochemical signs of androgen excess. FPHL has been reported in complete androgen 
insensitivity syndrome,(26) and in the absence of circulating androgens.(27) Although antiandrogens 
are used in the treatment of FPHL the evidence of benefit from controlled trials is lacking. Finasteride 
1 mg daily had no effect in a controlled trial in postmenopausal women with FPHL(28) although two 
uncontrolled case series using higher doses of finasteride have reported improvement.(29, 30) In a 
one-year trial comparing cyproterone acetate with topical minoxidil hair loss progressed in women 
taking cyproterone acetate (but improved in the minoxidil group).(31) Paradoxically, a questionnaire 
study in women receiving testosterone implants for symptoms of androgen deficiency reported an 
improvement in hair growth (although almost all developed hirsutism).(32) Androgen levels in women 
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decline progressively from early in the 4th decade(33) and this parallels the gradual reduction in scalp 
hair density and hair diameter in the female population that occurs with advancing age.(3) It was 
suggested that testosterone may have an anabolic effect on hair growth that is distinct from a virilising 
effect via the 5Į-reductase pathway. 
The possible role of oestrogen in FPHL is similarly uncertain. The oestrogen receptor beta is 
expressed in human hair follicles(34) and oestrogens exhibit stimulating effects on the generation of 
the hair shaft and the proliferation of keratinocytes of the hair matrix, with prolongation of the anagen 
phase, in cultivated male hair follicles.(35) Indirect evidence for a protective effect of oestrogens on 
human hair growth comes from the increasing prevalence of FPHL following the menopause, the 
prolongation of anagen during pregnancy(36) and reports of hair loss in women taking tamoxifen or 
aromatase inhibitors for treatment of breast cancer.(37) One study found lower oestrogen:androgen 
ratios in premenopausal women with FPHL compared to a control group, suggesting a protective 
effect of oestrogen on hair loss, although the number of subjects was quite small.(38) Interestingly, 
androgen levels were slightly lower in the FPHL subjects than in controls though the difference was 
not significant. On the other hand there is no clear effect of oestrogen supplements on human hair 
growth and several studies have shown an inhibitory effect of oestrogens on hair growth in other 
species.(39-41)  
Prostaglandins  
Prostaglandins have been implicated in the pathogenesis of male balding.(42) Garza et al. showed 
elevated levels of prostaglandin D2 synthase (PTGDS) mRNA and protein in bald compared to haired 
scalp. The product of its activity, prostaglandin D2 (PGD2) was also elevated in bald scalp, and 
inhibited hair growth in explanted human follicles and when applied topically to mice. K14-Ptgs2 
transgenic mice, which show elevated PGD2 in the skin, developed alopecia and miniaturisation of 
hair follicles. Further experiments in transgenic mice and cultured human follicles indicated the 
inhibitory effect of PGD2 on hair growth was via the GPR44 receptor. It is not yet known whether these 
results are applicable to FPHL.        
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Iron stores, Vitamin D  
The place of low iron stores in the aetiology of FPHL is controversial. Both lower (43, 44) and similar 
(45) serum ferritin levels compared to control groups have been reported in women with FPHL. There 
are no controlled trials that have tested the hair growth response to iron supplementation in women 
with FPHL. One study reported a response to antiandrogen therapy in women with serum ferritin levels 
above 40 ȝg/l but not in those with serum ferritins below this level.(46) 
Recently, Banihashemi et al. found lower vitamin D3 levels in a sample of 45 women with FPHL than in 
45 control subjects.(47) Rasheed et al. reported significantly decreased serum ferritin and serum 
vitamin D2 levels in 80 women with either chronic telogen effluvium or FPHL compared to 40 age-
matched healthy females.(48) Fawzi et al observed decreased serum and tissue levels of vitamin D 
receptors (VDRs) in 20 patients with AGA.(49) VDR levels were significantly higher in female patients 
with AGA than in males. There are no published studies on the hair growth response to vitamin D 
supplementation in women with FPHL and vitamin D deficiency. 
 
Dickkopf-1/ WNT signalling pathway  
In a sample of 24 patients with AGA (including either M-AGA or FPHL) and 31 patients with alopecia 
areata (AA) and 33 healthy controls of Egyptian origin, a significantly higher concentration of tissue 
DKK-1 (Dickkopf 1) levels was detected in AGA patients compared to controls.(50) DKK-1, a secreted 
glycoprotein, is an antagonist of the Wnt signaling pathway.(51) Wnt, itself a proto-oncoprotein, can 
promote cell proliferation and transformation when mutated or overexpressed. Of note, in M-AGA, 
genome-wide significance was found for the variant rs7349332 on chr2q35, which is located 
intronically in WNT10.(52) Expression studies in human hair follicle tissue suggest that WNT10A has a 
functional role in M-AGA etiology. Interestingly, Tosti et al. applied methyl vanillate (MV), an activator 
of the WNT/ß-catenin signalling to 20 female patients with FPHL. They demonstrated increase of hair 
count and hair mass index in the patients as well as increased WNT10B mRNA expression levels in 
affected scalp skin.(53) 
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Comorbidities 
A number of studies have reported an increased frequency of features of metabolic syndrome in 
women with FPHL including obesity, insulin resistance, hypertension, hyperprolactinaemia and raised 
aldosterone levels.(54-58) An increased risk of carotid and coronary artery disease has also been 
reported.(55, 59, 60) Birch et al. reported a significantly raised BMI in women with hirsutism, both with 
and without FPHL, but BMI levels were not raised in non-hirsute women with FPHL.(61) A study from 
Turkey found an association between FPHL and insulin resistance that appeared to be independent of 
hyperandrogenaemia.(62)   
Although research points to comorbidity, current studies are limited by i) small sample sizes, ii) small 
control groups, iii) lack of population-based data (Berkson`s bias) and iv) lack of homogeneous, 
standardized examination methods. To further elucidate the comorbidity profile in FPHL and to shed 
light on a possible influence of comorbidity on disease severity, systematic studies in larger 
population-based samples are a necessary step.  
 
Heritable Factors - the present status of FPHL genetic research  
Mode of inheritance 
Two twin studies from Australia and Denmark have shown that M-AGA is largely determined by 
genetic factors, with heritability in the region of 80-95%.(63, 64) In the first published family study, 
Dorothy Osborn concluded that pattern hair loss is due to a single gene and is inherited as an 
autosomal dominant trait in men and autosomal recessive in women.(65) This idea was subsequently 
questioned by Küster and Happle who proposed a polygenic model of inheritance,(66) although, like 
Osborn, they assumed that male and female pattern hair loss are the same entity. The polygenic 
hypothesis for M-AGA is now generally accepted and supported by results of GWAS. Less is known 
about the role of genetic factors in FPHL. Smith and Wells reported that balding was more common in 
first-degree male relatives of 56 women with hair loss than women without hair loss, suggesting a 
common genetic influence.(67) On the other hand, a twin study in older women found no evidence of a 
genetic component to hair thinning although there was a strong heritable influence on fronto-temporal 
recession.(68) Clinical observation suggests that early-onset FPHL is inherited but it is notable that 
this study was performed in similarly aged subjects and drawn from the same population as the 
Danish study that demonstrated strong heritability in male balding.(64)  
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Molecular genetic studies   
To understand the complex biological cascades behind polygenic disorders, such as M-AGA, genome-
wide association studies (GWAS) are suitable for the identification of genetic variants on a given locus 
which will help in the elucidation of the biological function behind the disease. This has recently been 
exemplified in M-AGA.(69) No genome-wide linkage or association studies of FPHL have been 
reported to date. Only a few candidate gene studies, primarily focussing on genes of the sex steroid 
hormone pathway and known M-AGA susceptibility loci, have been performed (Table 1); these and 
others are discussed in the following sections.  
 
Sex steroid hormone pathway 
Association studies between the genes for aromatase (CYP19A1) and oestrogen receptor 2 (ESR2) 
with FPHL were performed in an Australian group of almost 500 affected women and 500 controls. 
Nominal significant association was obtained for three variants of each of the two genes; however, 
these results did not withstand correction for multiple testing.(70, 71) We intended to replicate the 
reported borderline associations of three SNPs and added an additional SNP within CYP19A1 in our 
FPHL sample of 200 patients of German and British origin; however we could not find any association, 
including for the rs4646 CC genotype which is known to be associated with higher oestrogen 
levels.(72) Rui et al. chose twelve SNPs in CYP19A1 and examined them in a cohort of 200 Chinese 
women with FPHL and a similar number of healthy controls. They found that rs6493497 and 
rs7176005 were significantly associated with FPHL without applying any multiple testing strategy.(73) 
In addition, the authors found no association with rs4646, which was among the top SNPs of the study 
by Yip et al.(70, 73)  
In another association study, we attempted to replicate the Australian findings for ESR2 with markers 
rs10137185, rs17101774 and rs2022748 in our German/UK FPHL case–control sample. In the 
German sample, no significant association was found for rs17101774 or rs2022748. However, 
significant association was found for rs10137185 in the overall sample (Puncorr. = 0.012); and the 
strongest association was found for rs10137185 in the late-onset FPHL subgroup (Puncorr. = 0.010).(74) 
We had earlier investigated four variants in the ESR2 gene in our German/UK FPHL sample and 
found no association.(75) However, this may have been attributable to the fact that none of these four 
variants were in strong linkage disequilibrium with variants showing association in the Australian 
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sample (max. r2 = 0.149). 
The latter study also included variants of other genes implicated in androgen, or other sex steroid, 
metabolism in women with FPHL: ESR1 (oestrogen receptor 1), PGR (progesterone receptor), as well 
as SRD5A1 and SRD5A2 (steroid-5-alpha-reductase, alpha polypeptide1 and 2); but no association 
was observed for any of the examined variants.(75) Due to the enormous number of single nucleotide 
polymorphisms (SNPs) in these genes we did not attempt to cover entirely the genes using a tagging 
SNP approach; instead we opted to genotype selected variants predicted to have functional effects. 
The involvement of these genes in the aetiopathogenesis of FPHL cannot, therefore, be completely 
excluded.  
M-AGA susceptibility loci 
To test the hypothesis that M-AGA and FPHL share the same aetiology we examined all gene loci 
respectively variants in FPHL that had previously been identified for M-AGA. These included 
AR/EDA2R,(76) and the chromosomal regions 1p36.22, 2q35, 2q37.3, 3q25.1, 5q33.3, 7p21.1, 
7q11.22, 12p12.1, 17q21.31, 18q21.1, and 20p11.(77-79)  
For the AR/EDA2R locus, we investigated 25 SNPs, based on their use in a recent fine mapping study 
of the association signal in M-AGA.(77) Genetic variability at the AR/EDA2R locus is thought to 
enhance the effect of androgens by increasing the number of androgen receptors in affected scalp 
tissue. We used a sample of 230 British and German women with FPHL. In the overall combined 
German and British samples no significant differences in allele or genotype frequencies were 
observed between patients and controls for any of the investigated variants at this locus. Subgroup 
analysis of British patients with an early age of onset generated nominally significant P-values for 
seven SNPs within AR/EDA2R, with the lowest P-value being obtained for rs1397631 (P = 0.00483, 
OR 0.16 [CI 0.04-0.69], P = 0.047 after adjustment for the testing of multiple SNPs). No association 
was found after stratification for disease severity.(76) Although the role of the locus AR/EDA2R in 
FPHL remains unclear, our results suggest that it may represent a common genetic factor for early 
onset FPHL and M-AGA.  Further research is warranted in larger FPHL sample sets, as the subgroup 
of early affected British women (n = 57) was relatively small.(76)   
Two other studies have investigated the association between the major M-AGA susceptibility locus, 
the X-chromosomal locus containing the androgen receptor (AR) and ectodysplasin A2 receptor 
(EDA2R) genes, and FPHL. These association studies, carried out in a very small Egyptian 
sample(80) and the above mentioned sample of Chinese Han women with FPHL,(81) were each 
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limited to the investigation of the CAG repeat length variant of the AR gene and no association 
between this and FPHL was found.(80, 81) Fine mapping studies of this locus in AGA have indicated 
that the CAG repeat length variant is unlikely to be the causative variant, and that other variants at this 
locus show much stronger association with AGA.(77)  
Susceptibility locus 20p11 
Chromosome 20p11 contains a further major susceptibility locus for M-AGA, for which no candidate 
gene has yet been identified. We genotyped the top five SNPs from the chromosome 20p11 region 
that reached genome-wide significance in a recent GWAS of M-AGA(78) in our FPHL sample of 230 
women. No significant association was obtained for the five 20p11 variants, in either the overall 
sample set or in subgroup analyses.(76) Our results do not implicate the 20p11 locus in the aetiology 
of FPHL. 
Further susceptibility loci; 1p36.22, 2q35, 2q37.3, 3q25.1, 5q33.3, 7p21.1, 7q11.22, 12p12.1, 
17q21.31, 18q21.1 
In larger cohorts of M-AGA a further ten susceptibility loci were identified. (52, 82, 83) We genotyped 
up to three variants from each of the newly identified loci in our FPHL sample, and were unable to 
demonstrate a significant association for any of the genotyped variants, in either the overall sample or 
in subgroup analyses.(84, 85)  
Melanocortin 4 receptor (MC4R) 
Recent studies suggested an association of metabolic syndrome - including obesity, hyperlipidaemia, 
hypertension and diabetes mellitus type 2 or abnormally high fasting blood glucose - with FPHL. As 
mutations in the melanocortin 4 receptor gene (MC4R) have been identified in patients with morbid 
obesity,(55, 86, 87) and about half of the women in our FPHL sample present with obesity, we 
considered MC4R as an interesting candidate gene. Furthermore, this neuropeptide receptor has 
been detected amongst others in the dermal papilla of the hair follicle.(88) However, none of the six 
variants examined showed any association with FPHL.(89) 
 
Conclusion of the molecular genetic data 
Female pattern hair loss and male balding share a final common pathway of follicular regression but 
current knowledge suggests the aetiology is not necessarily the same in both sexes. Androgens are a 
key driver of male balding and are also involved in the aetiology of pattern hair loss in some women. 
However, it is likely that other non-androgenic factors, as yet unidentified, play a role in causing FPHL. 
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The idea that the aetiologies of FPHL and M-AGA are not necessarily identical is supported by the 
results of genetic studies. The predisposition to M-AGA is largely due to heritable factors. Although 
only some of the loci identified as associated with M-AGA have been examined for FPHL, not even the 
most significant AR/EDA2R locus for M-AGA (p = 1 x 10-320) showed a clear susceptibility for FPHL: 
other than the association of seven AR/EDA2R markers in the small group of 57 British patients with 
early onset, no clear overlap of susceptibility loci between M-AGA and FPHL could be demonstrated 
by any of the published studies. These results, therefore, point to distinct risk loci in the two disorders 
and to different underlying pathomechanisms. Similarly, the attempt to investigate the candidate genes 
of the sex steroid hormone pathway failed to demonstrate significant association with FPHL. This 
provides further support to the hypothesis that unexpected disease-causing mechanisms lead to the 
development of FPHL. Two very recent studies have substantially increased the number of gene loci 
(>60) that associate with M-AGA.(90, 91) These findings have yet to be investigated or replicated in 
FPHL. Similar studies employing a GWAS approach are sorely needed in FPHL if we are to clarify the 
uncertainties over its aetiology and pathophysiology, and potentially to develop new approaches to its 
treatment.   
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Table 1: Candidate gene studies  
Gene/ 
Locus 
Function Population Results Reference 
AR/EDA2R 
M-AGA susceptibility 
locus 
  Significant association of 
seven variants in a subgroup 
of British women with an 
early age of onset 
Redler et al., Br J Dermatol 2012 UK & Germany  
  
AR/EDA2R 
M-AGA susceptibility 
locus 
 Han Chinese No significant association Rui et al., Dermatology 2016 
1p36 
M-AGA susceptibility 
locus 
UK & Germany  No significant association Redler et al., J Dermatol Sci 2013  
2q35 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
Nuwayhid et al., Arch Dermatol Res 
2014 
2q37 
M-AGA susceptibility 
locus 
UK & Germany  No significant association Redler et al., J Dermatol Sci 2013  
3q25.1 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
Nuwayhid et al., Arch Dermatol Res 
2014 
5q33.3 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
7p21.1 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
Redler et al., J Dermatol Sci 2013  
7q11.22 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
12p12.1 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
Nuwayhid et al., Arch Dermatol Res 
2014 
17q21.31 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
Redler et al., J Dermatol Sci 2013  
18q21.1 
M-AGA susceptibility 
locus 
UK & Germany  No significant association 
20p11 
M-AGA susceptibility 
locus 
UK & Germany  No significant association Redler et al., Br J Dermatol 2012 
CYP19A1 
Sex steroid hormone 
pathway 
Australia 
CC genotype of rs4646 
significantly more frequent in 
cases than controls compared 
with collapsed AC and AA 
Yip et al., Br J Dermatol 2009  
CYP19A1 
Sex steroid hormone 
pathway 
UK & Germany  No significant association Redler et al., Br J Dermatol 2011 
CYP19A1 
Sex steroid hormone 
pathway 
Han Chinese 
Association for variants 
rs6493497, rs7176005 
Rui et al., Dermatology 2016 
ESR1 
Sex steroid hormone 
pathway 
UK & Germany  No significant association Redler et al., Exp Dermatol 2012 
ESR2 
Sex steroid hormone 
pathway 
UK & Germany  No significant association Redler et al., Exp Dermatol 2012 
ESR2 
Sex steroid hormone 
pathway 
Australia 
Nominal significance for the 
variants rs10137185, 
rs17101774, rs2022748 
Yip et al., Br J Dermatol 2012 
ESR2 
Sex steroid hormone 
pathway 
  Significant association for 
rs10137185 in the overall 
German sample 
Redler et al., Brit J Dermatol 2012 UK & Germany  
  
PGR 
Sex steroid hormone 
pathway
UK & Germany  No significant association Redler et al., Exp Dermatol 2012 
SRD5A1 
Sex steroid hormone 
pathway 
UK & Germany  No significant association Redler et al., Exp Dermatol 2012 
SRD5A2 
Sex steroid hormone 
pathway 
UK & Germany  No significant association Redler et al., Exp Dermatol 2012 
MC4R 
Melanocortin 
receptor gene 
UK & Germany  No significant association 
Mahmoudi & Redler et al., Arch 
Dermatol Res 2012 
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Figure legends 
Figure 1 
Female pattern hair loss. Diffuse reduction in hair density affecting the mid and frontal regions of the 
scalp with retention of the frontal hairline.  
 
 
